AstraZeneca Cancer Drug Selumetinib Fails in Lung TrialBy and
Medicine didn’t help patients live longer or without disease
Setback comes days after Opdivo from Bristol-Myers disappoints
AstraZeneca Plc’s experimental medicine selumetinib failed to keep a common form of lung cancer at bay in an advanced clinical test, making it the second drugmaker to report a setback in battling tumors of the lung this month.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.